Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of SYS6043 versus investigator's choice chemotherapy in platinum-resistant advanced ovarian, primary peritoneal, or fallopian tube cancer
CTR20262713Phase 3Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SYS6043 in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Jul 2026; status: active.
02
Drugs
SYS6043
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on CTR20262713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262713.